Literature DB >> 31796888

Dapagliflozin for HFrEF - improved outcomes across all ages.

Karina Huynh1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31796888     DOI： 10.1038/s41569-019-0321-z

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  2 in total

Review 1.  Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues.

Authors:  Javed Butler; Milton Packer; Stephen J Greene; Mona Fiuzat; Stefan D Anker; Kevin J Anstrom; Peter E Carson; Lauren B Cooper; Gregg C Fonarow; Adrian F Hernandez; James L Januzzi; Mariell Jessup; Rita R Kalyani; Sanjay Kaul; Mikhail Kosiborod; JoAnn Lindenfeld; Darren K McGuire; Marc S Sabatine; Scott D Solomon; John R Teerlink; Muthiah Vaduganathan; Clyde W Yancy; Norman Stockbridge; Christopher M O'Connor
Journal:  Circulation       Date:  2019-12-16       Impact factor: 29.690

2.  Increased Myocardial Stiffness in Patients With High-Risk Left Ventricular Hypertrophy: The Hallmark of Stage-B Heart Failure With Preserved Ejection Fraction.

Authors:  Michinari Hieda; Satyam Sarma; Christopher M Hearon; Katrin A Dias; Jose Martinez; Mitchel Samels; Braden Everding; Dean Palmer; Sheryl Livingston; Margot Morris; Erin Howden; Benjamin D Levine
Journal:  Circulation       Date:  2019-12-23       Impact factor: 29.690
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.